Abstract: The present invention provides a process for preparation of racemic voriconazole in a single reaction vessel. The present invention also provides a process for preparation of voriconazole using racemic voriconazole and the process of making it therewith.

Abstract: A dog tug apparatus includes a housing having a dispensing portion and a tug device configured to extend from and retract back into the housing. The tug device includes a tug having teeth scrubbing bristles extending there from. A resistance assembly resists unwinding of the tug line, and includes first and second opposing electromagnets suspended about the periphery of a slotted metal disk. A controller can adjust the resistance applied by the resistance assembly and provide an audible signal at the end of an exercise event. A recovery mechanism provides a means for rewinding the tug line about the spool after the tug line has been unwound, such as during a dog exercise event. In use, the rotation of the spool in the direction to unwind the tug line rotates a reduction gear system and results in the rotation of a treat dispensing mechanism to dispense a dog treat.

Abstract: The present invention provides a compound of general formula (9), useful as potential antitumour agents against human cancer cell lines. The present invention further provides a process for the preparation of pyrrolo[2,1-c][1,4][benzodiazepine g hybrids of general formula (9).

Abstract: The present invention relates to a process for the preparation of zofenopril and its pharmaceutically acceptable salts and a pharmaceutical composition thereof. The present invention also provides structurally novel compounds, which are useful intermediates in the synthesis of zofenopril.

Abstract: The present invention generally relates to a process for the preparation of fosaprepitant dimeglumine intermediate and its use in the preparation of fosaprepitant dimeglumine; to a neutral form of fosaprepitant in a solid state and processes for the preparation thereof; and to a stable amorphous fosaprepitant dimeglumine, having a stability at temperatures of about 2° C. to about 8° C. and at a relative humidity below at least 60%; and a process for the preparation thereof.

Abstract: The invention relates generally to biotechnology, and more specifically to in silico methods of identifying lead molecules that have an increased probability of becoming an approved medicament, and business methods of identifying molecules such that they have an increased probability of becoming an approved medicament. Provided is a method for identifying a biologically active peptide consisting of two to seven amino acid residues, comprising the steps of providing a database comprising a plurality of naturally occurring polypeptide sequences; defining at least one peptide motif that satisfies certain defined criteria; and determining for the defined peptide motif its frequency of occurrence among the polypeptide sequences in the database and correlating the frequency with the biological activity of the peptide.

Abstract: The present invention provides an amorphous bupropion hydrobromide and an amorphous bupropion hydrobromide granulates with at least one pharmaceutically acceptable carrier, and a process for its preparation.

Abstract: The present invention relates to a process for the preparation of 3-(2-chloroethyl)-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrrido[1,2-a]-pyrimidin-4-one; and its use in the synthesis of paliperidone.

Abstract: A process for characterization of hepatocytes cells in goat comprising isolating goat hepatocytes and characterizing the isolated hepatocytes by biochemical and molecular techniques to demonstrate the hepatic functions.

Abstract: The invention relates to the field of drug development against acute radiation injury caused by exposure to high-energy electromagnetic waves (X-rays, gamma rays) or particles (alpha particles, beta particles, neutrons). To date, there is no effective drug to ameliorate radiation injury after accidental exposure to ionizing irradiation. The invention provides a method of treating radiation injury of a subject in need thereof comprising administering to the subject a peptide, or functional analogue or derivative thereof, of smaller than 30 amino acids. Furthermore, the invention provides use of a peptide, or functional analogue or derivative thereof, of smaller than 30 amino acids for the production of a pharmaceutical composition for the treatment of a subject suffering from or believed to be suffering from radiation injury. In particular, the invention provides anti-radiation peptides having a dose reduction factor (DRF) against acute gamma irradiation of at least 1.

Abstract: The present invention relates to amorphous form of bazedoxifene acetate and a process for the preparation thereof.

Abstract: The present invention provides novel solid milnacipran in crystalline form-G and a process for its preparation. The present invention also provides a process for the preparation of milnacipran hydrochloride from the novel solid crystalline milnacipran.

Abstract: The invention relates to the field of immunology. Specifically, the invention relates to the field of immune-mediated disorders such as allergies, auto-immune disease, transplantation-related disease or inflammatory disease. The invention provides for an immunoregulator (IR), use of an IR in preparing a pharmaceutical composition for treating an immune-mediated disorder and a method for treating an immune-mediated disorder.

Abstract: The present invention relates to a process for the preparation of esomeprazole magnesium dihydrate, specifically, esomeprazole magnesium crystalline dihydrate form A; and pharmaceutical compositions thereof.

Abstract: The present invention relates to processes for the preparation of bosentan and compounds that can be used as structurally novel intermediates for the synthesis thereof, and a pharmaceutical composition of the same.

Abstract: Methods of treating radiation injury of a subject in need thereof comprising administering to the subject a peptide consisting of the amino acid sequence AQGV. The invention provides for administration of the amino acid composition prior to and following exposure of the subject to a source of radiation.

Abstract: A method for suppressing data is provided that includes receiving a first packet communicated by an end user and identifying a difference in a comfort noise level associated with a second packet received as compared to the first packet. The second packet may be communicated without a data payload in cases where the difference in comfort noise level associated with the second packet as compared to the first packet is below a predetermined threshold.

Abstract: The present invention provides a compound of general formula (9), useful as potential antitumour agents against human cancer cell lines. The present invention further provides a process for the preparation of pyrrolo[2,1-c][1,4][benzodiazepine g hybrids of general formula (9).

Abstract: The present invention generally relates to an amorphous form of varenicline and its pharmaceutically acceptable salts thereof. More particularly the present invention relates to amorphous forms of varenicline and its L-tartrate salt; a process for their preparation and pharmaceutical compositions comprising the same.

Abstract: The invention relates to the field of drug development against acute radiation injury caused by exposure to high-energy electromagnetic waves (X-rays, gamma rays) or particles (alpha particles, beta particles, neutrons). To date, there is no effective drug to ameliorate radiation injury after accidental exposure to ionizing irradiation. The invention provides a method of treating radiation injury of a subject in need thereof comprising administering to the subject a peptide, or functional analogue or derivative thereof, of smaller than 30 amino acids. Furthermore, the invention provides use of a peptide, or functional analogue or derivative thereof, of smaller than 30 amino acids for the production of a pharmaceutical composition for the treatment of a subject suffering from or believed to be suffering from radiation injury. In particular, the invention provides anti-radiation peptides having a dose reduction factor (DRF) against acute gamma irradiation of at least 1.